Loading
Latest filing published 05 Nov 2024 for Protalix BioTherapeutics, Inc..
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Eyal Rubin (finance chief) discloses dealings in 2 companies, chiefly Protalix BioTherapeutics, Inc. and Brainstorm Cell Therapeutics Inc. Between 20 November 2017 and 23 September 2024, the trades on record add up to 7 filings.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
The newest entry dates from 5 November 2024: a share grant, in Protalix BioTherapeutics, Inc. Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
4 of 4 declarations